Leapcure delivered 40% of all enrollments on a resistant hypertension study during our engagement.

Resistant hypertension fails on eligibility and adherence, not patient scarcity. Leapcure confirms true treatment resistance, multiple prior antihypertensive classes, verified adherence, and rules out white-coat and masked hypertension, before a referral ever reaches a site.

Talk to our resistant hypertension teamSee how it works →
50
Patients pre-screened and referred to site
by Leapcure on a resistant hypertension study
~50%
Of Leapcure referrals projected to reach site screening
internal funnel projection, pending Sales confirmation
8
Patients scheduled for official site screening
on the same study

Understanding Resistant Hypertension as a Clinical Trial Indication

Resistant hypertension is blood pressure that stays above goal despite three or more antihypertensive medications of different classes at optimal doses, ideally including a diuretic. It is common in the broader hypertensive population, so on its surface a trial looks easy to fill. The difficulty is not finding people with high blood pressure; it is confirming the patients who are genuinely treatment-resistant and eligible.

For sponsors, that is where enrollment breaks down. A resistant hypertension protocol requires confirming true treatment resistance across multiple prior antihypertensive classes, verifying medication adherence, and ruling out white-coat and masked hypertension and other causes of pseudo-resistance, all before a patient is worth a site's screening slot. Comorbidity burden is high, and generic, volume-led recruitment floods sites with patients who are not actually resistant or not adherent, burying coordinators while enrollment stalls. This is a condition that fails on eligibility and adherence, not availability.

Leapcure pre-screens against exactly those criteria before referral, which is why our referrals convert to site screening at a meaningfully higher rate than a raw-lead handoff would. On a resistant hypertension study where other agencies were also recruiting, Leapcure delivered 40% of all enrollments during our engagement, and pre-screened and referred 50 patients to site, with 8 scheduled for official site screening. That approach is backed by recruitment infrastructure proven across other structurally hard-to-enroll conditions: 44 patient referrals against a competing agency's 2 on a Phase 2 Lupus Nephritis rescue, 100% of final enrollments on a completed multi-agency Phase 2 Myasthenia Gravis program, and 40+ patients enrolled on a Phase 3 Major Depressive Disorder study at roughly 3x the rate of other agencies. The same model, qualify hard, support patients through to the site, and outperform when we are one of several agencies on a study, underpins how Leapcure approaches resistant hypertension.

The Challenge

Resistant hypertension fails on eligibility and adherence, not patient scarcity. Confirming true resistance, verifying adherence, and ruling out pseudo-resistance all have to happen before a site is burdened.

Confirming true treatment resistance

Eligibility hinges on genuine resistance across three or more antihypertensive classes at optimal doses. Patients who look resistant on paper often are not, and sending them to sites unconfirmed wastes screening slots and inflates screen fails.

Leapcure pre-screens against true-resistance criteria before referral, delivering 40% of all enrollments on a resistant hypertension study during our engagement, where other agencies were also recruiting.

Verifying medication adherence

Uncontrolled blood pressure is frequently an adherence problem, not a resistance one. Protocols require confirmed adherence before enrollment, and that verification is a recruiting task in itself, one that generic outreach skips.

Leapcure confirms adherence before referral, which is why our referrals convert to site screening at a meaningfully higher rate than a raw-lead handoff; 50 patients were pre-screened and referred to site.

Ruling out white-coat and masked hypertension

Pseudo-resistance from white-coat or masked hypertension can disqualify a patient a site would otherwise screen. Identifying and excluding these cases early protects the site's limited screening capacity.

Leapcure's pre-screening rules out common causes of pseudo-resistance before referral, so sites receive patients worth a screening slot; 8 patients were scheduled for official site screening.

High comorbidity burden in a competitive, multi-agency field

Resistant hypertension patients often carry diabetes, kidney, and cardiovascular comorbidities, and sponsors frequently run several recruitment agencies at once. Standing out means qualifying harder and supporting patients further, not just sending more leads.

Leapcure outperforms when it is one of several agencies on a study: 44 referrals against a competing agency's 2 on a Phase 2 Lupus Nephritis rescue, and 100% of final enrollments on a completed Phase 2 Myasthenia Gravis program.

Three steps. One strategy built for your resistant hypertension trial.

Leapcure qualifies hard against true resistance and adherence, supports patients through to the site, and optimizes weekly, the same model that delivered 40% of all enrollments during our engagement on a resistant hypertension study.

1

Activate targeted channels for the resistant population

We reach the resistant hypertension population through targeted digital and community channels mapped to your eligibility criteria and site geographies. The advocacy channel is in development for this indication, so we lead with the channels already proven to surface qualified patients.

2

Pre-screen for eligibility and adherence before referral

Every referral is engaged and pre-screened before a site sees the patient. We confirm true treatment resistance across prior antihypertensive classes, verify adherence, and rule out white-coat and masked hypertension, so sites receive patients worth a screening slot rather than raw leads.

3

Support patients to site screening and optimize weekly

We support qualified patients through to official site screening and track referral quality and conversion continuously, rebalancing channels weekly toward where enrollment can move fastest. That discipline is why our referrals convert to screening at a meaningfully higher rate than a raw-lead handoff.

40% of all enrollments on a resistant hypertension study, during our engagement.

Challenge Context

Resistant hypertension study

Leapcure delivered 40% of all enrollments during our engagement, on a study where other agencies were also recruiting.

Pre-screening funnel

50 patients pre-screened and referred to site by Leapcure, with 8 scheduled for official site screening.

Cross-portfolio track record

Recruitment proven across other structurally hard-to-enroll conditions: a Phase 2 Lupus Nephritis rescue, a completed Phase 2 Myasthenia Gravis program, and a Phase 3 Major Depressive Disorder study.

Results & Metrics

Study enrollment share

40% of all enrollments on a resistant hypertension study during our engagement.

Pre-screened and referred

50 patients pre-screened and referred to site by Leapcure.

Scheduled for site screening

8 patients scheduled for official site screening on the same study.

Cross-portfolio outperformance

44 Leapcure referrals against a competing agency's 2 on a Phase 2 Lupus Nephritis rescue; 100% of final enrollments on a completed Phase 2 Myasthenia Gravis program; 40+ enrolled at roughly 3x other agencies on a Phase 3 Major Depressive Disorder study.

Four capabilities. Built to qualify hard. Ready for resistant hypertension.

Leapcure reaches and qualifies resistant hypertension patients through pre-screening for true treatment resistance, multi-agency collaboration, patient support through screening, and answer-engine visibility delivered to your trial.

Pre-Screening for True Treatment Resistance

  • •Every referral is pre-screened for genuine resistance across prior antihypertensive classes, verified adherence, and exclusion of white-coat and masked hypertension.
  • •This is why Leapcure's referrals convert to site screening at a meaningfully higher rate than a raw-lead handoff would.
  • •On a resistant hypertension study, this delivered 40% of all enrollments during our engagement.

Multi-Agency Collaboration

  • •Sponsors often run several recruitment agencies at once, and Leapcure is built to outperform in that setting rather than compete for the same raw leads.
  • •On a Phase 2 Lupus Nephritis rescue, Leapcure delivered 44 referrals against a competing agency's 2; on a completed Phase 2 Myasthenia Gravis program, 100% of final enrollments.
  • •We coordinate cleanly alongside other agencies while qualifying harder than a volume handoff.

Patient Support Through Screening

  • •A high-touch Patient Success team supports qualified patients from first contact through official site screening, so they do not drop off before they reach a site.
  • •On a Phase 3 Major Depressive Disorder study, this support helped enroll 40+ patients at roughly 3x the rate of other agencies.
  • •Sustained support, not a one-time lead push, is what keeps a comorbid, complex population engaged.

Answer-Engine and AI-Search Visibility

  • •Patients increasingly ask ChatGPT, Perplexity, and Google's AI Overview which trials they may be eligible for. We make your trial's information genuinely retrievable for those engines.
  • •We do this with crawlable, factually rich content, cited sources, and presence in the community and ClinicalTrials.gov sources AI engines actually cite, not schema tricks or content written for machines.
  • •This puts your resistant hypertension study where high-intent patients are already searching.

Living with resistant hypertension? A clinical trial may be an option.

If your blood pressure stays high despite several medications, a clinical trial may offer access to investigational treatments alongside your regular care, never instead of it. We know resistant hypertension is often managed alongside diabetes, kidney, and heart conditions, and that eligibility can involve confirming your medications and blood-pressure history. Leapcure's team explains what a trial involves, answers your questions honestly, and supports you at your pace.

See if a resistant hypertension trial may be right for you
Leapcure kangaroo mascot

Leapcure delivered 40% of all enrollments on a resistant hypertension study during our engagement, pre-screening for true treatment resistance and adherence so sites receive patients worth a screening slot. That approach is backed by recruitment proven across other structurally hard-to-enroll conditions in Lupus Nephritis, Myasthenia Gravis, and Major Depressive Disorder. Talk to our resistant hypertension team about your active or upcoming study.

Talk to our resistant hypertension team